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Background
Elicitation of a potent and broadly neutralizing antibody
response is the main goal of an effective HIV-1 vaccine.
Considering that all the described and available broadly
neutralizing MAbs target the envelope glycoproteins of
HIV-1, a vaccine aiming to induce such a response must
be based on HIV-1 envelopes. In particular, it has been
shown by us and others that the expression of env glyco-
proteins on the surface of particulate structures, such as
virosomes, pseudovirions or virus-like particles (VLPs),
could be a more efficient way to deliver conformational
epitopes to the immune system. Moreover, it has been
lately proposed that a broadly neutralizing antibody
response could be induced by focusing the immune
response on envelope regions known to be target for
broadly neutralizing monoclonal antibodies.
Methods
Aim of this study is to produce in a Baculovirus expression
system, within the FP7 EU-funded NGIN project, VLPs
based on HIV Pr55gag protein, displaying on their surface
either the gp140 HIV-1 envelope glycoproteins or the
HIV-1 gp41 sequences covering the ectodomain region.
Mutations in the gp140 glycoprotein sequence have been
introduced in order to stabilize gp120-gp41 association as
well as gp41-gp41 interaction and overcome the structural
instability of env trimers.
Results
Molecular constructs containing different transmembrane
sequences have been generated for the A-clade gp140
characterized in our laboratory as well as for gp41 regions
to evaluate the expression of envelope molecules on the
surface of VLPs. Recombinant Baculovirus DNAs have
been used for VLP production in High5 insect cells and
purified particles have been analyzed for protein expres-
sion.
Conclusion
The generation of VLPs expressing on their surface either
trimeric gp140 env glycoproteins or gp41 domains will
allow the evaluation of humoral response induction in
vivo and the broadness of its neutralizing activity against a
panel of autologous and heterologous field isolates.
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